VERACYTE, INC. Cost of Revenue
VERACYTE, INC. (VCYT) reported Cost of Revenue of $36.08 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-25.
Discontinued › Expense Statement
us-gaap:CostOfRevenue · last filed 2020-05-06
- VERACYTE, INC. cost of revenue for the quarter ending 2019-12-31 was $9.67M, a 11.13% increase year-over-year.
- VERACYTE, INC. cost of revenue for the quarter ending 2019-09-30 was $9.11M, a 10.33% increase year-over-year.
- VERACYTE, INC. cost of revenue for the quarter ending 2019-06-30 was $8.78M, a 6.44% increase year-over-year.
- VERACYTE, INC. cost of revenue for the quarter ending 2019-03-31 was $8.51M, a 8.21% increase year-over-year.
- VERACYTE, INC. cost of revenue for fiscal 2019 was $36.08M, a 9.07% increase from fiscal 2018.
- VERACYTE, INC. cost of revenue for fiscal 2018 was $33.08M, a 17.32% increase from fiscal 2017.
- VERACYTE, INC. cost of revenue for fiscal 2017 was $28.20M, a 10.73% increase from fiscal 2016.
- VERACYTE, INC. cost of revenue for fiscal 2016 was $25.46M, a 18.44% increase from fiscal 2015.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|
| 2019-12-31 | $9.67M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $18.79M derived: sum of 2 quarters · filed 2020-02-25 | $27.56M derived: sum of 3 quarters · filed 2020-02-25 | $36.08M 10-K · filed 2020-02-25 |
| 2019-09-30 | $9.11M 10-Q · filed 2019-10-22 | $17.89M derived: sum of 2 quarters · filed 2019-10-22 | $26.40M 10-Q · filed 2019-10-22 | $35.11M derived: sum of 4 quarters · filed 2020-05-06 |
| 2019-06-30 | $8.78M 10-Q · filed 2019-07-30 | $17.29M 10-Q · filed 2019-07-30 | $25.99M derived: sum of 3 quarters · filed 2020-05-06 | $34.26M derived: sum of 4 quarters · filed 2020-05-06 |
| 2019-03-31 | $8.51M 10-Q · filed 2020-05-06 | $17.22M derived: sum of 2 quarters · filed 2020-05-06 | $25.48M derived: sum of 3 quarters · filed 2020-05-06 | $33.72M derived: sum of 4 quarters · filed 2020-05-06 |
| 2018-12-31 | $8.70M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $16.96M derived: sum of 2 quarters · filed 2020-02-25 | $25.21M derived: sum of 3 quarters · filed 2020-02-25 | $33.08M 10-K · filed 2020-02-25 |
| 2018-09-30 | $8.26M 10-Q · filed 2019-10-22 | $16.51M derived: sum of 2 quarters · filed 2019-10-22 | $24.37M 10-Q · filed 2019-10-22 | $32.14M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-06-30 | $8.25M 10-Q · filed 2019-07-30 | $16.11M 10-Q · filed 2019-07-30 | $23.88M derived: sum of 3 quarters · filed 2020-02-25 | $31.05M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-03-31 | $7.87M 10-Q · filed 2019-04-30 | $15.64M derived: sum of 2 quarters · filed 2020-02-25 | $22.80M derived: sum of 3 quarters · filed 2020-02-25 | $29.77M derived: sum of 4 quarters · filed 2020-02-25 |
| 2017-12-31 | $7.77M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $14.94M derived: sum of 2 quarters · filed 2020-02-25 | $21.90M derived: sum of 3 quarters · filed 2020-02-25 | $28.20M 10-K · filed 2020-02-25 |
| 2017-09-30 | $7.17M 10-Q · filed 2018-10-29 | $14.13M derived: sum of 2 quarters · filed 2018-10-29 | $20.43M 10-Q · filed 2018-10-29 | $26.94M derived: sum of 4 quarters · filed 2019-02-25 |
| 2017-06-30 | $6.96M 10-Q · filed 2018-07-23 | $13.26M 10-Q · filed 2018-07-23 | $19.77M derived: sum of 3 quarters · filed 2019-02-25 | $26.14M derived: sum of 4 quarters · filed 2019-02-25 |
| 2017-03-31 | $6.30M 10-Q · filed 2018-05-01 | $12.81M derived: sum of 2 quarters · filed 2019-02-25 | $19.18M derived: sum of 3 quarters · filed 2019-02-25 | $25.48M derived: sum of 4 quarters · filed 2019-02-25 |
| 2016-12-31 | $6.51M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-25 | $12.88M derived: sum of 2 quarters · filed 2019-02-25 | $19.18M derived: sum of 3 quarters · filed 2019-02-25 | $25.46M 10-K · filed 2019-02-25 |
| 2016-09-30 | $6.37M 10-Q · filed 2017-11-07 | $12.67M derived: sum of 2 quarters · filed 2017-11-07 | $18.95M 10-Q · filed 2017-11-07 | $25.12M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-06-30 | $6.30M 10-Q · filed 2017-07-31 | $12.58M 10-Q · filed 2017-07-31 | $18.75M derived: sum of 3 quarters · filed 2018-02-27 | $24.37M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-03-31 | $6.28M 10-Q · filed 2017-05-03 | $12.45M derived: sum of 2 quarters · filed 2018-02-27 | $18.07M derived: sum of 3 quarters · filed 2018-02-27 | $23.21M derived: sum of 4 quarters · filed 2018-02-27 |
| 2015-12-31 | $6.17M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $11.79M derived: sum of 2 quarters · filed 2018-02-27 | $16.93M derived: sum of 3 quarters · filed 2018-02-27 | $21.50M 10-K · filed 2018-02-27 |
| 2015-09-30 | $5.62M 10-Q · filed 2016-11-03 | $10.76M derived: sum of 2 quarters · filed 2016-11-03 | $15.32M 10-Q · filed 2016-11-03 | $20.19M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | $5.14M 10-Q · filed 2016-08-03 | $9.71M 10-Q · filed 2016-08-03 | $14.57M derived: sum of 3 quarters · filed 2017-03-01 | $18.74M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | $4.57M 10-Q · filed 2016-05-05 | $9.43M derived: sum of 2 quarters · filed 2017-03-01 | $13.60M derived: sum of 3 quarters · filed 2017-03-01 | $17.57M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | $4.87M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $9.03M derived: sum of 2 quarters · filed 2017-03-01 | $13.00M derived: sum of 3 quarters · filed 2017-03-01 | $16.61M 10-K · filed 2017-03-01 |
| 2014-09-30 | $4.17M 10-Q · filed 2015-11-05 | $8.13M derived: sum of 2 quarters · filed 2015-11-05 | $11.74M 10-Q · filed 2015-11-05 | $15.21M derived: sum of 4 quarters · filed 2016-03-14 |
| 2014-06-30 | $3.97M 10-Q · filed 2015-08-13 | $7.57M 10-Q · filed 2015-08-13 | $11.04M derived: sum of 3 quarters · filed 2016-03-14 | $14.18M derived: sum of 4 quarters · filed 2016-03-14 |
| 2014-03-31 | $3.61M 10-Q · filed 2015-05-15 | $7.08M derived: sum of 2 quarters · filed 2016-03-14 | $10.21M derived: sum of 3 quarters · filed 2016-03-14 | $13.44M derived: sum of 4 quarters · filed 2016-03-14 |
| 2013-12-31 | $3.47M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14 | $6.60M derived: sum of 2 quarters · filed 2016-03-14 | $9.83M derived: sum of 3 quarters · filed 2016-03-14 | $12.61M 10-K · filed 2016-03-14 |
| 2013-09-30 | $3.13M 10-Q · filed 2014-11-13 | $6.36M derived: sum of 2 quarters · filed 2014-11-13 | $9.14M 10-Q · filed 2014-11-13 | $11.74M derived: sum of 4 quarters · filed 2015-03-25 |
| 2013-06-30 | $3.23M 10-Q · filed 2014-08-14 | $6.00M 10-Q · filed 2014-08-14 | $8.60M derived: sum of 3 quarters · filed 2015-03-25 | $10.59M derived: sum of 4 quarters · filed 2015-03-25 |
| 2013-03-31 | $2.77M 10-Q · filed 2014-05-09 | $5.37M derived: sum of 2 quarters · filed 2015-03-25 | $7.36M derived: sum of 3 quarters · filed 2015-03-25 | |
| 2012-12-31 | $2.60M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-25 | $4.58M derived: sum of 2 quarters · filed 2015-03-25 | $7.58M 10-K · filed 2015-03-25 | |
| 2012-09-30 | $1.98M 10-Q · filed 2013-11-25 | $4.98M 10-Q · filed 2013-11-25 | ||
| 2011-12-31 | $2.92M 10-K · filed 2014-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| BIODESIX INC (BDSX) | United States | $0.312B |